Loading...

Oragenics

DB:UAVP
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
UAVP
DB
$22M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • Oragenics has significant price volatility in the past 3 months.
UAVP Share Price and Events
7 Day Returns
-2.9%
DB:UAVP
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-63.2%
DB:UAVP
-5.6%
DE Biotechs
-4.5%
DE Market
UAVP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Oragenics (UAVP) -2.9% -17.9% -46.2% -63.2% -94.6% -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • UAVP underperformed the Biotechs industry which returned -5.6% over the past year.
  • UAVP underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
UAVP
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Oragenics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Oragenics. This is due to cash flow or dividend data being unavailable. The share price is €0.43.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Oragenics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Oragenics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:UAVP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.87
AMEX:OGEN Share Price ** AMEX (2019-04-25) in USD $0.48
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Oragenics.

DB:UAVP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:OGEN Share Price ÷ EPS (both in USD)

= 0.48 ÷ -0.87

-0.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oragenics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Oragenics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Oragenics's expected growth come at a high price?
Raw Data
DB:UAVP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-3.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Oragenics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Oragenics's assets?
Raw Data
DB:UAVP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.50
AMEX:OGEN Share Price * AMEX (2019-04-25) in USD $0.48
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:UAVP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:OGEN Share Price ÷ Book Value per Share (both in USD)

= 0.48 ÷ 0.50

0.96x

* Primary Listing of Oragenics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oragenics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Oragenics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Oragenics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Oragenics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-3.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Oragenics expected to grow at an attractive rate?
  • Unable to compare Oragenics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Oragenics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Oragenics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:UAVP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:UAVP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -3.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:UAVP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:UAVP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 10 1
2022-12-31 0 1
2021-12-31 0 -12 2
2020-12-31 0 -1 -12 2
2019-12-31 0 -1 -11 2
DB:UAVP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -9 -11
2018-09-30 -7 -10
2018-06-30 -6 -8
2018-03-31 -6 -7
2017-12-31 -6 -7
2017-09-30 -7 -8
2017-06-30 -7 -8
2017-03-31 -7 -8
2016-12-31 -7 -8
2016-09-30 -7 -8
2016-06-30 -6 -8
2016-03-31 0 -5 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Oragenics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Oragenics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:UAVP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Oragenics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UAVP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.01 0.01 0.01 1.00
2022-12-31 -0.31 -0.31 -0.31 1.00
2021-12-31 -0.27 -0.22 -0.31 2.00
2020-12-31 -0.24 -0.23 -0.25 2.00
2019-12-31 -0.26 -0.26 -0.26 1.00
DB:UAVP Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.87
2018-09-30 -1.44
2018-06-30 -1.52
2018-03-31 -1.39
2017-12-31 -1.37
2017-09-30 -1.62
2017-06-30 -1.60
2017-03-31 -1.79
2016-12-31 -1.90
2016-09-30 -1.93
2016-06-30 -2.06
2016-03-31 -3.36

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Oragenics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Oragenics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Oragenics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Oragenics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Oragenics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Oragenics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Oragenics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Oragenics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Oragenics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Oragenics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UAVP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -11.33 4.02 5.97
2018-09-30 -10.03 3.59 4.99
2018-06-30 -7.93 3.33 4.41
2018-03-31 -6.87 3.11 3.74
2017-12-31 -6.73 3.18 3.54
2017-09-30 -7.95 3.51 4.50
2017-06-30 -7.89 3.65 4.47
2017-03-31 -8.41 3.80 4.65
2016-12-31 -8.50 3.79 4.75
2016-09-30 -8.03 3.71 4.32
2016-06-30 -7.93 3.41 4.46
2016-03-31 -0.36 -12.62 3.08 9.28
2015-12-31 -11.84 3.05 8.73
2015-09-30 0.22 -10.84 3.00 7.94
2015-06-30 0.42 -9.97 2.81 7.43
2015-03-31 1.09 -5.44 3.37 2.73
2014-12-31 0.94 -5.79 3.32 3.07
2014-09-30 1.15 -7.65 4.87 9.59
2014-06-30 1.21 -15.94 6.86 9.90
2014-03-31 1.07 -16.12 7.20 9.63
2013-12-31 1.03 -16.07 7.54 9.36
2013-09-30 1.03 -14.98 6.47 3.02
2013-06-30 1.04 -8.21 5.50 2.71
2013-03-31 1.13 -13.06 4.82 8.25
2012-12-31 1.33 -13.09 5.02 7.86
2012-09-30 1.30 -13.04 4.95 7.97
2012-06-30 1.38 -12.29 4.72 7.94

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Oragenics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Oragenics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Oragenics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Oragenics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Oragenics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Oragenics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Oragenics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Oragenics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Oragenics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Oragenics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 176.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Oragenics Company Filings, last reported 3 months ago.

DB:UAVP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 20.88 0.12 20.21
2018-09-30 13.98 0.19 13.81
2018-06-30 3.65 0.02 3.94
2018-03-31 4.32 0.07 4.76
2017-12-31 6.32 0.08 6.17
2017-09-30 1.01 2.53 2.92
2017-06-30 0.51 2.42 2.09
2017-03-31 1.19 0.06 2.18
2016-12-31 2.97 0.07 4.08
2016-09-30 4.49 0.11 5.12
2016-06-30 5.24 0.03 5.46
2016-03-31 2.87 0.08 3.37
2015-12-31 4.73 0.06 5.08
2015-09-30 1.50 5.11 6.74
2015-06-30 3.09 5.03 8.04
2015-03-31 9.16 0.08 9.05
2014-12-31 10.34 0.06 10.45
2014-09-30 11.56 0.11 11.76
2014-06-30 12.56 0.04 12.90
2014-03-31 14.20 0.08 14.64
2013-12-31 15.84 0.06 16.28
2013-09-30 4.36 2.06 8.27
2013-06-30 5.68 0.14 6.37
2013-03-31 7.65 0.07 8.35
2012-12-31 9.23 0.05 9.93
2012-09-30 10.83 0.09 11.76
2012-06-30 -1.45 2.09 1.13
  • Oragenics's level of debt (0.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.4% vs 0.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Oragenics has sufficient cash runway for 2.2 years based on current free cash flow.
  • Oragenics has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 9.5% each year.
X
Financial health checks
We assess Oragenics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Oragenics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Oragenics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Oragenics dividends.
If you bought €2,000 of Oragenics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Oragenics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Oragenics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:UAVP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:UAVP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Oragenics has not reported any payouts.
  • Unable to verify if Oragenics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Oragenics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Oragenics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Oragenics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Oragenics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Oragenics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Oragenics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alan Joslyn
COMPENSATION $456,569
AGE 59
TENURE AS CEO 2.8 years
CEO Bio

Dr. Alan F. Joslyn, Ph.D., has been Chief Executive Officer and President of Oragenics Inc. since June 06, 2016. Dr. Joslyn serves as an Executive-in-Residence at Care Capital, LLC. Dr. Joslyn served as the President and Chief Executive Officer at Mt. Cook Pharma from March 2007 to March 2009. From August 2009 to October 2012, he served as the Chief Executive Officer of Edusa Pharmaceuticals, Inc. and served as its President. He served as a Senior Vice President of Research and Development at Penwest Pharmaceuticals Co. from June 2004 to 2007, where he led its efforts in transitioning from a drug delivery company to a specialty pharmaceutical company developing treatments for nervous system disorders. From March 2010 to April 2014, Dr. Joslyn was a Drug Development Consultant to Sentinella Pharmaceuticals. From March 2010 to April 2014, Dr. Joslyn served as Chief Executive Officer and a Director of Sentinella Pharmaceuticals. Since April 2014, Dr. Joslyn was a Partner at Lazarus Pharmaceuticals, LLC. From 1995 to 2004, Dr. Joslyn held a number of leadership positions at Johnson & Johnson, primarily focusing on the development of Gastroenterology products including Propulsid, Motilium, Aciphex and prucalopride. He served as the Vice President of Internal Medicine at Johnson & Johnson Pharmaceutical Research and Development. From 1995 to 2004, Dr. Joslyn held a series of leadership positions at Johnson & Johnson's Janssen Research Foundation in Global Drug Development. Dr. Joslyn has been an Independent Director of Synergy Pharmaceuticals, Inc. since October 2008. Dr. Joslyn has been a Director of Oragenics Inc. since June 06, 2016. He was a Director of Clinical Research at Glaxo Research Institute from 1988 to 1995 and Edusa Pharmaceuticals, Inc. from August 2009 to October 2012, Mt. Cook Pharma, Inc. since March 2007. He holds a Ph.D. in Biochemical Pharmacology in 1986, B.A. in biology and Bachelor of Sciences degree in medical chemistry from State University of New York at Buffalo in 1981.

CEO Compensation
  • Alan's compensation has increased whilst company is loss making.
  • Alan's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Oragenics management team in years:

5.7
Average Tenure
59
Average Age
  • The average tenure for the Oragenics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Alan Joslyn

TITLE
President
COMPENSATION
$457K
AGE
59
TENURE
2.8 yrs

Mike Sullivan

TITLE
CFO, Secretary & Treasurer
COMPENSATION
$311K
AGE
62
TENURE
7.2 yrs

Martin Handfield

TITLE
Senior Vice President of Discovery Research
COMPENSATION
$217K
AGE
47
TENURE
4.3 yrs

Raman Bedi

TITLE
Chairman of International Scientific Advisory Board and Senior Consultant
TENURE
13.3 yrs
Board of Directors Tenure

Average tenure and age of the Oragenics board of directors in years:

12.8
Average Tenure
66
Average Age
  • The average tenure for the Oragenics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Fred Telling

TITLE
Chairman
COMPENSATION
$205K
AGE
66
TENURE
8.2 yrs

Alan Joslyn

TITLE
President
COMPENSATION
$457K
AGE
59
TENURE
2.8 yrs

Raman Bedi

TITLE
Chairman of International Scientific Advisory Board and Senior Consultant

Charlie Pope

TITLE
Independent Director
COMPENSATION
$175K
AGE
66
TENURE
8.8 yrs

Per-Erik Saris

TITLE
Member of Scientific Advisory Board

Howard Kuramitsu

TITLE
Member of Scientific Advisiory Board

Hari Parkash

TITLE
Member of Scientific Advisory Board
TENURE
12.8 yrs

Brian Mouatt

TITLE
Member of International Scientific Advisory Board
TENURE
12.8 yrs

Eli Schwarz

TITLE
Member of Scientific Advisory Board
TENURE
12.8 yrs

Ayyaz Khan

TITLE
Member of Scientific Advisory Board
TENURE
12.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Sep 18 Buy Robert Koski Individual 14. Sep 18 18. Sep 18 169,050 €0.36 €60,521
X
Management checks
We assess Oragenics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Oragenics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring chemical agent for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013; a license agreement with LPThera LLC to develop LPT3-04; and a license agreement Texas A&M University System for access to new homologs of the lantibiotic MU1140 and other lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

Details
Name: Oragenics, Inc.
UAVP
Exchange: DB
Founded: 1996
$20,058,118
46,112,303
Website: http://www.oragenics.com
Address: Oragenics, Inc.
4902 Eisenhower Boulevard,
Suite 125,
Tampa,
Florida, 33634,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX OGEN Common Stock NYSE MKT LLC US USD 09. Jul 2003
DB UAVP Common Stock Deutsche Boerse AG DE EUR 09. Jul 2003
Number of employees
Current staff
Staff numbers
6
Oragenics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:42
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.